Paul Bonanos
banner
biobonanos.bsky.social
Paul Bonanos
@biobonanos.bsky.social
I write some, I edit some
Congrats to you and your team, Craig!
November 17, 2025 at 1:37 PM
Six. Six weeks after resubmission. But five weeks after today: Sept. 26, 2025.
August 22, 2025 at 12:19 PM
So good, and it never gets old. He asked three people to come make a record, they all said yes, and they all aced the assignment. He had ten songs, and there are no outtakes. Lightning in a bottle. web.archive.org/web/20250208...
July 23, 2025 at 3:19 PM
John Hiatt was living month-to-month when he signed with A&M in 1987. He made 'Bring the Family' in four days, bunking at a Holiday Inn with his three band members, Nick Lowe, Ry Cooder and Jim Keltner. Two years later, Bonnie Raitt's cover of "Thing Called Love" made him a wealthy man.
Thing Called Love
YouTube video by John Hiatt - Topic
www.youtube.com
July 23, 2025 at 3:09 PM
Fab. And you don't have to be a Bay City Rollers fan to love a song about going to see them play -- with their real names in the lyrics: www.youtube.com/watch?v=MKKE...
Nick Lowe - "Rollers Show" (Official Audio)
YouTube video by Yep Roc Records
www.youtube.com
July 23, 2025 at 2:00 PM
Those are all staples in this household. (Look how much we love Nick.)
July 23, 2025 at 1:28 PM
Good question, and it's good to see activity in the vaccine arena, especially 10-figure M&A.

I can't speak to Sanofi's risk calculus, but the pharma did say the deal allows it “to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.”
July 22, 2025 at 2:25 PM
And here's our story on Merck/Verona. The pharma gets a drug with multibillion-dollar potential, a first-in-class therapy for a large indication with plenty of unmet need. The deal is also a morale boost for the U.K. biotech arena, with potential to recycle talent back into the sector.
Merck to gain fast-selling COPD therapy via $10B Verona buyout
In Robert Davis’ third 11-figure deal since ascending to the CEO role in 2021, Merck is paying $10 billion to obtain a fast-growing therapy for...
www.biocentury.com
July 9, 2025 at 5:55 PM
Here's my 2022 story about SpliceBio, from the time of its series A. The company uses engineered inteins to reassemble large proteins in vivo after they're delivered via separate AAV vectors: www.biocentury.com/article/6422...
Splice Bio: gene therapies that reassemble large proteins in vivo
Gene therapy company Splice Bio has attracted the largest series A funding in history for a Spanish biotech as it advances a lead ophthalmology progra...
www.biocentury.com
June 11, 2025 at 4:46 PM